English
Back
Download
Log in to access Online Inquiry
Back to the Top
avatar
Trytosaveabit commented on a stock · Aug 13, 2024 03:13

Note some dates / timeframe

$Lisata Therapeutics (LSTA.US)$Has some anticipated clinical milestones set for the next 18 months. Multiple clinical studies are advancing, with the Phase 2b ASCEND study in metastatic pancreatic ductal adenocarcinoma having completed enrollment for one of its cohorts, with results expected by the fourth quarter of 2024. The BOLSTER and CENDIFOX trials are progressing as planned, and the study of certepetide in glioblastoma multiforme has started dosing. These developments suggest that Lisata Therapeutics is on a clear path to potential future approvals and the design of a subsequent Phase 3 trial
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
3333 Views
Comment
Sign in to post a comment
    avatar
    Trytosaveabit
    4924
    Followers
    24
    Following
    70K
    Visitors
    Follow
    Heat List
    US
    SymbolMini ChartPrice
    NVDA
    NVIDIA
    -- 139.400
    INTC
    Intel
    -- 27.390
    TSLA
    Tesla
    -- 354.110
    GRAB
    Grab Holdings
    -- 5.300
    SMCI
    Super Micro Computer
    -- 55.800
    Discussing
    Trump 2.0 Era: How will global markets evolve?
    🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
    MicroStrategy Q4 2024 earnings conference call
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.